EQS-News: Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.
- These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.
- The data was presented this week at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders ( AD/PD™ 2024: advances in science and therapy ).
- “The positive results presented at AD/PD™ 2024 demonstrate how treatment with GAL-201 has a potential neuroprotective effect and may also improve cognitive function.
- Furthermore, they validate that toxic Aβ oligomers and protofibrils are a major underlying cause of this devastating disease, and not the deposited forms of Aβ.